share_log

Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024

Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024

Chimerix公司將於2024年8月13日發佈第二季度財務報告並提供運營更新。
Chimerix ·  08/06 00:00

DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview.

Chimerix(NASDAQ:CMRX)是一家生物製藥公司,其使命是開發能顯着改善和延長面臨致命疾病患者的生命的藥品。今天宣佈,將於2024年8月13日星期二上午8:30(東部時間)舉行電話會議和網絡直播,以報告截至2024年6月30日的第二季度財務業績和業務概況。

To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5436125. A live audio webcast of the call will also be available on the Investors' section of the Company's website, . An archived webcast will be available on the Chimerix website approximately two hours after the event.

接聽直播電話請提前五分鐘撥打(646) 307-1963(美國境內)或(800)715-9871(國際長途),並提供會議ID 5436125。調取本次電話會議的網絡直播,請在公司網站的投資者版塊收聽。本次活動結束後大約兩個小時,的Chimerix網站將提供已存檔的網絡直播。

About Chimerix

關於Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

Chimerix是一家生物製藥公司,旨在開發有意義地改善和延長面對致命疾病的患者生命的藥物。該公司最先進的臨床階段開發項目ONC201正在開發治療的H3K27M突變性膠質瘤。

CONTACT:

聯繫人:

Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com

威爾·奧康納
Stern Investor Relations
212-362-1200
will@sternir.com


big

Source: Chimerix, Inc.

來源:錘子醫藥股份有限公司。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論